☆ 4.7 Editorial Material

Nivolumab and sorafenib in hepatocellular carcinoma: lessons from the CheckMate 459 study Comment

LANCET ONCOLOGY (2022)

Get Full Text
Add to Collection

Journal

LANCET ONCOLOGY
Volume 23, Issue 1, Pages 4-6

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1470-2045(21)00651-3

Keywords

-

Categories

Oncology

Funding

  1. Instituto de Salud Carlos III [PI15/00145, PI18/0358, FI19/00222]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.